SCHEMBL14729709

SCHEMBL14729709

Fc1cccc(Cl)c1-c1cc(OCc2ccccc2)c(OCc2ccccc2)nn1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 2/20 0.41
MRGPRX4 Q96LA9 4/20 0.40
HTR1A P08908 2/20 0.40
SLC6A2 P23975 1/20 0.40
SLC6A4 P31645 1/20 0.40
SLC6A3 Q01959 1/20 0.40
NPC1 O15118 3/20 0.40
HPGD P15428 2/20 0.40
NFKB1 P19838 2/20 0.40
RAB9A P51151 2/20 0.40
NFKB2 Q00653 2/20 0.40
RELA Q04206 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
MEN1 O00255 1/20 0.40
MITF O75030 1/20 0.40
TP53 P04637 1/20 0.40
XBP1 P17861 1/20 0.40
KMT2A Q03164 1/20 0.40
ADRA1D P25100 1/20 0.39
ADRA1A P35348 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14729715 0.91 KDM1A (0.46) KDM1AMRGPRX4HTR1ASLC6A2SLC6A4
SCHEMBL14718840 0.81 NPC1 (0.40) KDM1AMRGPRX4HTR1ASLC6A2SLC6A4
SCHEMBL14729662 0.80 BRD4 (0.43) HTR1ASLC6A4NPC1HPGDNFKB1
SCHEMBL14729678 0.80 PTGER1 (0.46) KDM1AMRGPRX4HTR1ASLC6A2SLC6A4
SCHEMBL14718539 0.78 MRGPRX4 (0.39) KDM1AMRGPRX4HTR1ASLC6A2SLC6A4
SCHEMBL14729657 0.75 PTGER1 (0.46) HPGD
SCHEMBL14729690 0.75 EGFR (0.45) EGFRERBB2MAPK14MAPTMAPK1
SCHEMBL14729696 0.75 MAOB (0.43) KDM1ANPC1RAB9ASMN1; SMN2MEN1
SCHEMBL14729707 0.75 SQOR (0.51) HTR1ANPC1RAB9ASMN1; SMN2MEN1
SCHEMBL14719395 0.75 SLC6A4 (0.44) HTR1ASLC6A4NPC1NFKB1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130052281-A1 NOVEL COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130052281-A1 NOVEL COMPOUNDS ABCG2, F12, UGT1A1 KDM1A 3048/4885MRGPRX4 97/4885HTR1A 822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.